| For: | Chai SY, Zhang RY, Ning ZY, Zheng YM, Swapnil R, Ji LN. Sodium-glucose co-transporter 2 inhibitors improve insulin resistance and β-cell function in type 2 diabetes: A meta-analysis. World J Diabetes 2025; 16(7): 107335 [PMID: 40697602 DOI: 10.4239/wjd.v16.i7.107335] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v16/i7/107335.htm |
| Number | Citing Articles |
| 1 |
Declan C McCann, Ben Martinez, Nathalia G O’Brien, Harvey N Mayrovitz. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors as Therapy for Hidradenitis Suppurativa and Other Inflammatory Skin Diseases: A Narrative Review. Cureus 2026; doi: 10.7759/cureus.110202
|
| 2 |
Iuliana Popescu, Robert C. Bunn, Phil Ray, Kathryn M. Thrailkill, John L. Fowlkes. The SGLT2 Inhibitor Canagliflozin Promotes β‐Cell Regeneration and Restores and Stabilises β‐Cell Identity in a Polygenic Model of Severe Early‐Onset Type 2 Diabetes. Journal of Cellular and Molecular Medicine 2026; 30(5) doi: 10.1111/jcmm.71041
|
| 3 |
Serafino Fazio, Flora Affuso. Insulin Resistance/Hyperinsulinemia Should Be Considered in the Prevention and Treatment of Essential Hypertension. Biomedicines 2025; 13(12) doi: 10.3390/biomedicines13123102
|
| 4 |
Ting-Tai Yen, Chuan Angel Lu, Tina Yi Jin Hsieh, Gin-Yi Lee, Changchuan Jiang, Edward J. Tanner. Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia. Gynecologic Oncology 2026; 211 doi: 10.1016/j.ygyno.2026.06.023
|
| 5 |
Joseph A. M. J. L. Janssen. Hypothesis: Nutrient Off-Loading and Ectopic Fat Reduction Reverse Insulin Resistance and Improve Cardiovascular Outcomes in Type 2 Diabetes—A Narrative Review. International Journal of Molecular Sciences 2026; 27(5) doi: 10.3390/ijms27052150
|
| 6 |
Charlotte Delrue, Reinhart Speeckaert, Marijn M. Speeckaert. Rewinding the Clock: Emerging Pharmacological Strategies for Human Anti-Aging Therapy. International Journal of Molecular Sciences 2025; 26(19) doi: 10.3390/ijms26199372
|
| 7 |
Gaurab Bhaduri, Supratik Bhattacharyya, Shatavisa Mukherjee, Rutul Gokalani. Decoupling weight loss from organoprotective benefits in GLP-1RA, dual agonists, and SGLT2I therapy: A narrative review. Acta Diabetologica 2026; 63(4) doi: 10.1007/s00592-025-02636-7
|
| 8 |
Daniel Basta, Assem Al Refaei, Linda Msinjili, William H. Frishman, Edward Lebovics. Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: Shared Mechanisms and Therapeutic Opportunities. Cardiology in Review 2026; doi: 10.1097/CRD.0000000000001298
|
| 9 |
Mohammad Baadkoube Hazaveh, Fatemeh Naseri Rad, Hani Ghadri, Mohammad Mahdi Kakoienejad, Seyed-Matin Emami-Alorizy, Omid Bahrami, Leila Goudarzimehr, Ali Heidari, Samira Eslami, Babak Goodarzy, Yasaman Vaseghi, Ali Rafatnia, Danyal Yarahmadi. Effect of SGLT2 inhibitor drugs on triglyceride-glucose (TyG) index in adults: A systematic review and meta-analysis. Primary Care Diabetes 2026; doi: 10.1016/j.pcd.2026.07.002
|